Form 4: Vir Biotechnology, Inc. (VIR), Scangos George A, transaction 03/10/2022

Summary

A Form 4 for George A. Scangos, a director and the President and CEO of Vir Biotechnology, Inc. (VIR), reporting awards dated 03/10/2022. Scangos acquired 111,000 restricted stock units under the issuer's Equity Incentive Plan, raising direct ownership to 223,989 shares, and a stock option for 222,000 shares at $29.48 expiring 03/09/2032. The option vests 25% on February 22, 2023, with the remainder in 36 equal monthly installments. The form lists indirect holdings, including 3,598,559 shares in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust, and shares in other family trusts. Howard Horn signed as Attorney-in-Fact on 04/06/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * SCANGOS GEORGE A (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 (Street) SAN FRANCISCO CA 94158 (City) (State) (Zip) | SCANGOS GEORGE A | (Last) | (First) | (Middle) | C/O VIR BIOTECHNOLOGY, INC. | 499 ILLINOIS STREET, SUITE 500 | SAN FRANCISCO | CA | 94158 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) President and CEO | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | President and CEO
3. Date of Earliest Transaction
 (Month/Day/Year) 03/10/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 03/10/2022 | A (1) | 111,000 | A | $ 0.00 | 223,989 | D
Common Stock | 3,598,559 | I | See footnote (2)
Common Stock | 61,660 | I | See footnote (3)
Common Stock | 877,135 | I | See footnote (4)
Common Stock | 61,660 | I | See footnote (5)
Common Stock | 877,135 | I | See footnote (6)
Common Stock | 115,000 | I | See footnote (7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (Right to Buy) | $ 29.48 | 03/10/2022 | A | 222,000 | (8) | 03/09/2032 | Common Stock | 222,000 | $ 0.00 | 222,000 | D
Explanation of Responses:
1. Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
2. The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
3. The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
4. The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
5. The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
6. The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
7. The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
8. 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.
Remarks:
/s/ Howard Horn, Attorney-in-Fact | 04/06/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_VIR_4_filed2022-04-06_0001209191-22-023524.xml

Size

20,445 bytes

SHA-256

2b0541cb3c6d366bb894e6069a67bc252b1750e369e6150f9806ebf34a730efc

Our copy

SEC_VIR_4_filed2022-04-06_0001209191-22-023524.xml

Original

www.sec.gov